What is Zacks Research’s Estimate for Integer Q1 Earnings?

Integer Holdings Corporation (NYSE:ITGR) – Stock analysts at Zacks Research lowered their Q1 2026 earnings estimates for shares of Integer in a report issued on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings of $1.31 per share for the quarter, down from their previous forecast of $1.39. The consensus estimate for Integer’s current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer’s Q2 2026 earnings at $1.57 EPS, Q3 2026 earnings at $1.73 EPS, Q4 2026 earnings at $1.79 EPS, FY2026 earnings at $6.40 EPS, Q1 2027 earnings at $1.51 EPS, Q3 2027 earnings at $1.88 EPS, Q4 2027 earnings at $1.86 EPS, FY2027 earnings at $6.95 EPS and FY2028 earnings at $7.57 EPS.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, February 19th. The medical equipment provider reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.70 by $0.06. Integer had a net margin of 5.55% and a return on equity of 13.26%. The business had revenue of $472.06 million during the quarter, compared to analysts’ expectations of $462.73 million. During the same period last year, the company posted $1.43 earnings per share. The business’s quarterly revenue was up 5.0% on a year-over-year basis. Integer has set its FY 2026 guidance at 6.290-6.780 EPS.

A number of other brokerages have also recently commented on ITGR. Wells Fargo & Company raised their price objective on Integer from $72.00 to $84.00 and gave the company an “equal weight” rating in a research note on Friday, February 20th. Weiss Ratings raised shares of Integer from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 24th. Citigroup upped their price objective on shares of Integer from $75.00 to $92.00 and gave the stock a “neutral” rating in a report on Friday, February 20th. Raymond James Financial reiterated an “outperform” rating and set a $101.00 price objective on shares of Integer in a report on Monday, February 23rd. Finally, Wall Street Zen lowered shares of Integer from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Four equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $102.00.

Integer Stock Performance

Shares of Integer stock opened at $83.43 on Thursday. The business has a 50-day simple moving average of $85.11 and a 200 day simple moving average of $86.18. Integer has a one year low of $62.00 and a one year high of $127.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.32 and a quick ratio of 2.23. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of 29.07, a PEG ratio of 1.46 and a beta of 0.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Salomon & Ludwin LLC increased its holdings in shares of Integer by 46.8% during the fourth quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 118 shares in the last quarter. Kestra Advisory Services LLC increased its stake in Integer by 0.6% during the 4th quarter. Kestra Advisory Services LLC now owns 21,424 shares of the medical equipment provider’s stock valued at $1,680,000 after purchasing an additional 136 shares in the last quarter. Orion Porfolio Solutions LLC increased its stake in Integer by 1.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 9,755 shares of the medical equipment provider’s stock valued at $1,200,000 after purchasing an additional 138 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Integer by 4.4% during the second quarter. Ameritas Investment Partners Inc. now owns 3,521 shares of the medical equipment provider’s stock valued at $433,000 after buying an additional 148 shares during the last quarter. Finally, Lido Advisors LLC grew its holdings in shares of Integer by 5.5% during the fourth quarter. Lido Advisors LLC now owns 2,887 shares of the medical equipment provider’s stock valued at $226,000 after buying an additional 151 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

Integer News Roundup

Here are the key news stories impacting Integer this week:

• Positive Sentiment: Board appointments and cooperation with an activist: Integer added James Flanagan as an independent director and agreed to a cooperation arrangement with Irenic Capital, which led to Aaron Kapito joining the board — a development that can accelerate governance/strategy reviews and is often viewed as a potential catalyst for shareholder value. Integer Appoints James Flanagan and Aaron Kapito to Board of Directors
• Positive Sentiment: Zacks raised longer-term estimates: Zacks Research increased its FY2027 and FY2028 EPS forecasts (FY2027 to $6.95 from $6.73; FY2028 to $7.57), signaling improved visibility for multi-year earnings power that can support a higher valuation if execution holds.
• Neutral Sentiment: Mixed quarter-level tweaks: Zacks lifted several quarterly estimates (notably Q2 2026 and Q4 2026/Q4 2027) while trimming others — these offsetting adjustments suggest analysts are refining timing of recovery/growth rather than changing the broad outlook dramatically.
• Negative Sentiment: Near-term cuts and a slight FY2026 trim: Zacks cut Q1 2026 (to $1.31 from $1.39) and trimmed Q3 2026 estimates modestly, and nudged FY2026 down to $6.40 (from $6.41). These near-term downgrades could pressure sentiment and earnings expectations for the next few quarters.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.